This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets

Santarus, Inc. (NASDAQ: SNTS) announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. UCERIS was approved by the U.S. Food and Drug Administration on January 14, 2013.

UCERIS contains budesonide, a locally acting glucocorticosteroid, in a novel oral tablet formulation that utilizes proprietary MMX ® multi-matrix system colonic delivery technology. The approved dosing regimen for adult patients is one 9 mg tablet taken orally once daily in the morning for up to 8 weeks.

“We believe that UCERIS fills an important therapeutic gap as a new prescription option available to physicians treating patients in the active phase of mild to moderate ulcerative colitis,” said Wendell Wierenga, Ph.D., executive vice president of research and development. “In our pivotal clinical studies, three times more patients achieved clinical remission and mucosal healing with UCERIS compared with patients taking placebo, and no clinically significant differences in glucocorticosteroid side effects were seen versus placebo after eight weeks of treatment.”

William C. Denby, senior vice president of commercial operations said, “For the commercial launch of UCERIS we have added 85 new sales representatives, increasing our total number of sales reps to 235. We will use the entire sales organization to promote UCERIS and ZEGERID ® (omeprazole/sodium bicarbonate) to gastroenterologists, while also continuing to promote our three diabetes/metabolic products to endocrinologists and other physicians.”

Mr. Denby added, “In addition to our physician outreach, we recognize that informing patients with ulcerative colitis about UCERIS is key to motivating them to seek treatment for the active phase of their disease. To that end, we are implementing patient education programs through social media and medical information websites to provide patients with helpful information about treatment options.”

UCERIS was developed in collaboration with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. Upon first commercial sale of UCERIS, $7 million is payable to Cosmo in cash or Santarus common stock, at Cosmo’s option.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.45 -1.50%
FB $116.90 0.15%
GOOG $694.00 0.43%
TSLA $246.12 -0.64%
YHOO $36.37 -0.60%


Chart of I:DJI
DOW 17,722.21 -108.55 -0.61%
S&P 500 2,061.89 -13.92 -0.67%
NASDAQ 4,772.9380 -32.3530 -0.67%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs